Make HER first-line count in the maintenance setting in newly diagnosed aOC

A decade of Lynparza in the UK: enhancing advanced ovarian cancer care and addressing persistent unmet patient needs^2-5

| Indication

Watch the video below to discover what Lynparza overall survival data could mean for patients with advanced ovarian cancer – giving more time for life’s planned and unplanned moments.

Overall Survival in the HRD-positive subgroup is based on an exploratory subgroup analysis

There remains a critical unmet need in advanced ovarian cancer survival and recurrence outcomes^4,5

Infographic showing that ~45% of women with aOC receiving surgery and chemotherapy do not survive beyond 5 years

Infographic showing that >80% of women with aOC receiving surgery and chemotherapy experience recurrence within 5 years

With aOC patients demonstrating decreasing treatment-free interval time over subsequent lines of therapy, the 1L maintenance treatment period is critical to give them a chance for long-term remission by following the ESMO recommended targeted approach to treatment selection^6-8

Long-term remission and delay of disease progression are key for patients with aOC. Without maintenance therapy, aOC patients demonstrate decreasing treatment-free interval over subsequent lines of therapy:^2,6-8

Infographic showing that aOC patients have shorter treatment-free intervals over subsequent lines of therapy without maintenance

*From a retrospective analysis of 461 patients with high-grade serous ovarian cancer diagnosed between 1996 and 2009 that used secondary data from multiple centres participating in the Cancer Genome Atlas study.

For targeted treatments such as Lynparza, HRD status has been shown to be a pivotal biomarker to guide treatment selection in the 1L maintenance setting⁹

Learn more about HRD testing

Nearly half of all patients with aOC are HRD-positive (incl. BRCAm) and could be eligible for a Lynparza regimen in the 1L maintenance setting, with or without bevacizumab, depending on BRCA status^1,2,8,10*

For HRD-positive BRCAm aOC patients
find out more about SOLO‑1 here

For all HRD-positive aOC patients, including non-BRCAm
find out more about PAOLA‑1 here

*Some patients may be ineligible for Lynparza or bevacizumab treatments due to contraindications or comorbidities. Please refer to the Summaries of Product Characteristics for full safety and prescribing information.¹

Lynparza tablets therapeutic indications¹

Lynparza tablets are indicated as monotherapy for:

The maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
The maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Lynparza in combination with bevacizumab is indicated for:

The maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

Please consult the SmPC for further information before making any prescribing decisions.

aOC, advanced Ovarian Cancer; ESMO, European Society for Medical Oncology; TFI, treatment-free interval; 1L, first-line ; HRD, homologous recombination deficiency; BRCAm, BRCA1 or BRCA2 mutation; FIGO, Fédération Internationale de Gynécologie et d’Obstétrique.

Lynparza (olaparib) Summary of Product Characteristics.
Ray-Coquard I, et al. Ann Oncol. 2023;34:681–692 (plus supplementary appendix).
DiSIlvestro P, et al. J Clin Oncol. 2023;41:609–617.
Marth C, et al. Cancer. 2022 Aug 15;128(16):3080-3089 (plus supplementary appendix).
De Felice F et al. Int J Gynecol Cancer. 2017 May;27(4):690-695.
Eng KH, et al. Gynecol Oncol. 2015;139:228–235;
Ledermann JA, et al. Ann Oncol. 2013;24:vi24–vi32.
Ray-Coquard I, et al. N Engl J Med. 2019;381:2416–2428 (plus supplementary appendix).
Ledermann J, et al. Ann Oncol. 2024;35:248–266.
Avastin (bevacizumab) Summary of Product Characteristics.

GB-73564 | Date of Preparation: July 2026

Privacy Policy Terms of Use Contact Us Information for General Public Accessibility
Cookie Preferences

GB-73578 | Date of Preparation: July 2026

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000).

A decade of Lynparza in the UK: enhancing advanced ovarian cancer care and addressing persistent unmet patient needs2-5

Watch the video below to discover what Lynparza overall survival data could mean for patients with advanced ovarian cancer – giving more time for life’s planned and unplanned moments.

There remains a critical unmet need in advanced ovarian cancer survival and recurrence outcomes4,5

With aOC patients demonstrating decreasing treatment-free interval time over subsequent lines of therapy, the 1L maintenance treatment period is critical to give them a chance for long-term remission by following the ESMO recommended targeted approach to treatment selection6-8

For targeted treatments such as Lynparza, HRD status has been shown to be a pivotal biomarker to guide treatment selection in the 1L maintenance setting9

Nearly half of all patients with aOC are HRD-positive (incl. BRCAm) and could be eligible for a Lynparza regimen in the 1L maintenance setting, with or without bevacizumab, depending on BRCA status1,2,8,10*

Lynparza tablets therapeutic indications1